biote Corp. 8-K/A

What Happened

• biote Corp. (BTMD) filed an 8-K on June 17, 2026 reporting that Robert Peterson was appointed Interim Chief Executive Officer and entered into an Amended and Restated Employment Agreement with the company effective June 12, 2026. The filing describes Mr. Peterson’s compensation, incentive opportunity, equity grants, severance and change-in-control protections.

Key Details

• Annual base salary: $658,800; annual incentive opportunity up to 72.5% of his then-current annualized base salary.
• Equity: stock option to purchase shares equal to 0.56% of outstanding common stock (measured as of June 8, 2026), plus an additional option of the same size if he is later appointed non-interim CEO.
• Severance/benefits: if terminated without cause or resigns for specified “good reason,” BioTE will continue base salary and reimburse COBRA health premiums for up to 12 months (subject to a signed release).
• Change-in-control protections: if termination without cause or for good reason occurs within one month before or 12 months after a change in control, BioTE will pay base salary and annual target bonus for 12 months, reimburse COBRA premiums for up to 12 months, and any unvested time‑based equity granted on/after the agreement’s effective date will fully vest (if termination occurs during the measurement period).

Why It Matters

• This filing affects governance and executive compensation: investors should note the company’s cost commitments (base pay, incentive target, equity grants) and potential cash/benefit obligations on termination or change in control.
• The equity grant and change-in-control vesting could dilute shareholders and accelerate insider ownership incentives tied to leadership transition.
• The full Amended and Restated Employment Agreement will be included in BioTE’s Form 10-Q for the quarter ending June 30, 2026 for more detail.